Physician profile
Daniel A Mullis
NPI 1245202035
$1,778.12
in general payments reported to CMS, 2019-2025
18 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $123 · 2021: $52.95 · 2022: $124 · 2023: $114 · 2024: $115 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Food and Beverage | $341.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,059.38 | 2020-2025 | |
| Medtronic, INC. | $180.31 | 2021-2025 | Transorb, Gi Genius, Nim Vital |
| Ethicon US, LLC | $146.52 | 2019-2022 | |
| Tela Bio, INC. | $79.28 | 2022-2024 | Ovitex 2s |
| Hologic Sales and Service, LLC | $43.94 | 2023 | Localizer |
| Myriad Genetic Laboratories, INC. | $32.15 | 2021-2025 | Myrisk |
| Vertex Pharmaceuticals Incorporated | $32.05 | 2025 | |
| Integra Lifesciences Corporation | $27.71 | 2022 | |
| Innocoll Pharmaceuticals Limited | $24.63 | 2021 | |
| Glaxosmithkline, LLC. | $23.59 | 2024 | Bexsero, Menveo, Pediarix |
| Baxter Healthcare | $21.94 | 2020 | |
| Cardinal Health 414 LLC | $18.67 | 2024 | |
| Bard Peripheral Vascular, INC. | $18.20 | 2020 | |
| Elucent Medical | $16.26 | 2025 | |
| Mallinckrodt Enterprises LLC | $14.87 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $14.35 | 2022 | |
| Focal Therapeutics, INC. | $13.26 | 2019 | |
| Axonics, INC. | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mullis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.